Mannkind (MNKD) Capital Expenditures Growth (1y) (2011 - 2026)
Mannkind (MNKD) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 143.40% |
| 10 | Mannkind | 1.25 Bn | 1.12 Bn | 82.66 Mn | -19.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.09% |
| Dec 31, 2025 | -206.74% |
| Sep 30, 2025 | -858.54% |
| Jun 30, 2025 | 211.25% |
| Mar 31, 2025 | -86.30% |
| Dec 31, 2024 | 124.16% |
| Sep 30, 2024 | -87.03% |
| Jun 30, 2024 | 84.44% |
| Mar 31, 2024 | -71.03% |
| Dec 31, 2023 | -491.85% |
| Sep 30, 2023 | 22.24% |
| Jun 30, 2023 | -1,310.69% |
| Mar 31, 2023 | 2,069.97% |
| Dec 31, 2022 | -112.16% |
| Sep 30, 2022 | 150.24% |
| Jun 30, 2022 | -49.67% |
| Mar 31, 2022 | 208.87% |
| Dec 31, 2021 | 123.34% |
| Sep 30, 2021 | -25,825.00% |
| Jun 30, 2021 | 606.00% |